Windward Bio AG has initiated a global Phase 2 clinical trial for HBM9378/WIN378, an antibody treatment for asthma developed in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE